ENDRA Life Sciences (NASDAQ: NDRA) is one of 48 public companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare ENDRA Life Sciences to related businesses based on the strength of its institutional ownership, risk, earnings, analyst recommendations, valuation, profitability and dividends.
Institutional and Insider Ownership
17.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 44.0% of shares of all “Electromedical equipment” companies are held by institutional investors. 11.4% of ENDRA Life Sciences shares are held by insiders. Comparatively, 15.9% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares ENDRA Life Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ENDRA Life Sciences||N/A||-326.97%||-233.06%|
|ENDRA Life Sciences Competitors||-286.93%||-140.79%||-18.41%|
Valuation and Earnings
This table compares ENDRA Life Sciences and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ENDRA Life Sciences||$10,000.00||-$9.80 million||-0.70|
|ENDRA Life Sciences Competitors||$1.21 billion||$130.86 million||14.64|
ENDRA Life Sciences’ rivals have higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and target prices for ENDRA Life Sciences and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ENDRA Life Sciences||0||0||3||0||3.00|
|ENDRA Life Sciences Competitors||253||691||1298||62||2.51|
ENDRA Life Sciences presently has a consensus price target of $6.00, suggesting a potential upside of 310.96%. As a group, “Electromedical equipment” companies have a potential upside of 21.12%. Given ENDRA Life Sciences’ stronger consensus rating and higher possible upside, research analysts clearly believe ENDRA Life Sciences is more favorable than its rivals.
Volatility and Risk
ENDRA Life Sciences has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences’ rivals have a beta of 1.60, suggesting that their average stock price is 60% more volatile than the S&P 500.
ENDRA Life Sciences rivals beat ENDRA Life Sciences on 9 of the 13 factors compared.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.